Immuron CEO, Steven Lydeamore, to host an investor webinar
MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (IMCIMRN, a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.
This release has been authorised by the directors of Immuron Limited.
|
COMPANY CONTACT:
Steven Lydeamore |
About Immuron
Immuron Limited (IMCIMRN is a commercial and clinical-stage Australian biopharmaceutical company with a proprietary technology platform focused on a novel class of orally delivered polyclonal antibodies produced from hyperimmune antibody-rich bovine colostrum, for prevention and treatment of gut-mediated diseases.
For more information visit: http://www.immuron.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
